Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106

Benzinga · 4d ago
Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $114 to $106.